Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Leukemia, Plasma Cell 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × sargramostim × 30 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT02339571 2026-05-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

NCT07169617 2026-05-13

Testing the SurVaxM Vaccine for Lung Cancer Prevention

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Thoracic

Lung Neoplasms

NCT05455658 2026-05-05

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

University of Washington

Phase 2 Active not recruiting
33 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡